A Single-arm, Open Label, Multi-center, Phase 2 Study of SHR-1210 in Recurrent/Metastatic Nasopharyngeal Carcinoma Patients Who Have Received Previous At Least Two Lines of Chemotherapy.
Phase of Trial: Phase II
Latest Information Update: 31 Aug 2018
Price : $35 *
At a glance
- Drugs Camrelizumab (Primary)
- Indications Nasopharyngeal cancer
- Focus Therapeutic Use
- Sponsors Jiangsu Hengrui Medicine Co.
- 23 Aug 2018 Status changed from not yet recruiting to recruiting.
- 21 Jun 2018 New trial record